Case Report: CD19 CAR-T therapy induces dual remission in AML-M2b patient with CNS-PTLD and relapse
This case demonstrates the efficacy and feasibility of CD19 CAR-T therapy for concomitant post-transplant AML-M2b relapse and CNS-PTLD, leveraging their shared CD19 expression. It provides clinical evidence that targeting a shared antigen with a single CAR-T product can effectively treat heterogeneous malignancies, offering a promising new strategy for such complex cases.
Authors
- Mingfeng Zhao (ORCID: https://orcid.org/0000-0002-5995-7558)
- Haibo Zhu (ORCID: https://orcid.org/0000-0003-3138-437X)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-1025-906X)
- Xia Xiao (ORCID: https://orcid.org/0000-0002-9874-5240)
Institutions
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1672392
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China